Experimental evidence for this translocation being a driver of B cell lymphomas was provided by one of the first mouse transgenic cancer models, in which the c-MYC gene was coupled to IgH μ enhancer sequences to establish the Eμ-Myc mouse line (Adams et al., 1985). The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.